Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

Abstract: A pressure vessel for storing fluid is disclosed. The pressure vessel includes a metallic liner comprising a cylindrical portion and a pair of ellipsoidal domes positioned at opposite ends of the cylindrical portion. Further, the pressure vessel includes a composite material wrapped over the cylindrical portion and the pair of ellipsoidal domes. The composite material is formed of a polymeric matrix reinforced with fibers, the composite material comprises of a combination of hoop layers and helical layers which are positioned in predetermined order with respect to each other. A hoop layer is wrapped over a cylindrical portion of the metallic liner of the pressure vessel and a helical layer is wrapped over both the cylindrical portion and the pair of ellipsoidal domes. The helical layer is wrapped on each of the pair of ellipsoidal domes in a manner that a helical angle is defined at an intersection between the cylindrical portion and the pair of ellipsoidal domes.

Abstract: The present invention relates to a synthesis of novel Zn(II)-based Metal Organic Frameworks having mixed organic ligands of 1,3,5-benzene tricarboxylic acid (BTC) and 2-methylimidazole (mIm) through a simple and economic solvothermal method. The synthesized MOFs has cuboids morphology having high surface area (1248 m2/g) capable of hydrogen adsorption at ?10° C. to 25° C. temperature and 100 bar pressure. The hydrogen adsorption capabilities of the novel MOFs are in the range of 23-0.2 weight percent.

Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize human mesothelin582-598 (IP-NGYLVLDLSMQEALS) (SEQ ID NO: 1) are disclosed. Anti-mesothelin binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are disclosed. Methods of reducing mesothelin shed from cell membranes, methods of reducing the activity of TNF? converting enzyme, methods of detecting the presence of cancer, and methods of treating or preventing cancer are also disclosed.

Abstract: The present invention relates to a synthesis of novel Zn(II)-based Metal Organic Frameworks having mixed organic ligands of 1,3,5-benzene tricarboxylic acid (BTC) and 2-methylimidazole (mIm) through a simple and economic solvothermal method. The synthesized MOFs has cuboids morphology having high surface area (1248 m2/g) capable of hydrogen adsorption at ?10° C. to 25° C. temperature and 100 bar pressure. The hydrogen adsorption capabilities of the novel MOFs are in the range of 23-0.2 weight percent.

Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize B-Cell Maturation Antigen (BCMA) are disclosed. Chimeric antigen receptors (CARs), anti-BCMA binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer and methods of treating or preventing cancer are also disclosed.

Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize human mesothelin582-598 (IP-NGYLVLDLSMQEALS) (SEQ ID NO: 1) are disclosed. Anti-mesothelin binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are disclosed. Methods of reducing mesothelin shed from cell membranes, methods of reducing the activity of TNF? converting enzyme, methods of detecting the presence of cancer, and methods of treating or preventing cancer are also disclosed.

Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

Abstract: The present disclosure discloses an electrode (300, 400, 500). The electrode (300, 400, 500) includes a substrate (302). Further, the electrode (300, 400, 500) includes a first conducting layer (304) disposed on the substrate (302). The first conducting layer (304) is formed of at least one of an Indium Tin Oxide (ITO) and a Fluorine-doped Tin Oxide (FTO). The electrode (300, 400, 500) also includes at least one semiconductor layer (308, 502) disposed on the first conducting layer (304). Further, the electrode (300, 400, 500) includes at least one connector (120, 402, 504) distributed across the first conducting layer (304) and adapted to conduct an electric current from the electrode (300, 400, 500).

Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize B-Cell Maturation Antigen (BCMA) are disclosed. Chimeric antigen receptors (CARs), anti-BCMA binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer and methods of treating or preventing cancer are also disclosed.

Abstract: A polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Splice Variant-Novel Gene Expressed in Prostate (SV-NGEP). Polynucleotides encoding SV-NGEP are also disclosed, as are vectors including these poynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies and immunoconjugages are disclosed that specifically bind SV-NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds SV-NGEP, or a polynucleotide encoding SV-NGEP. Assays are disclosed for the detection of prostate cancer. Pharmaceutical compositions including an SV-NGEP polypeptide, an antibody that specifically binds SV-NEGP, or a polynucleotide encoding SV-NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.